The Lung in Primary Immunodeficiencies: New Concepts in Infection and Inflammation. Front Immunol 2018;9:1837
Date
08/28/2018Pubmed ID
30147696Pubmed Central ID
PMC6096054DOI
10.3389/fimmu.2018.01837Scopus ID
2-s2.0-85054929479 (requires institutional sign-in at Scopus site) 67 CitationsAbstract
Immunoglobulin replacement therapy (IGRT) has contributed critically to the management of primary antibody deficiencies (PAD) and the decrease in pneumonia rate. However, despite adequate IGRT and improved prognosis, patients with PAD continue to experience recurrent respiratory tract infections, leading to bronchiectasis and continuing decline in lung function with a severe impact on their quality of life. Moreover, non-infectious inflammatory and interstitial lung complications, such as granulomatous-lymphocytic interstitial lung disease, contribute substantially to the overall morbidity of PAD. These conditions develop much more often than appreciated and represent a major therapeutic challenge. Therefore, a regular assessment of the structural and functional condition of the lung and the upper airways with appropriate treatment is required to minimize the deterioration of lung function. This work summarizes the knowledge on lung complications in PAD and discusses the currently available diagnostic tools and treatment options.
Author List
Baumann U, Routes JM, Soler-Palacín P, Jolles SMESH terms used to index this publication - Major topics in bold
AnimalsHumans
Immunity
Immunization, Passive
Immunoglobulins, Intravenous
Immunologic Deficiency Syndromes
Inflammation
Lung
Respiratory System
Respiratory Tract Infections
